Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a clinical-stage biomedical company focused on developing high-impact therapies for cardiovascular and other high-unmet-need conditions. The company went public through a merger with Health Assurance Acquisition Corp (HAAC), a healthcare-focused special purpose acquisition company that completed its initial public offering in 2020 and was sponsored by HAAC Holdings, LLC, with backing from General Catalyst. The Form 425 communication filed on July 5, 2022 was submitted in connection with the then-pending business combination, which subsequently closed in early 2023, with the combined company trading under the OBIO ticker on Nasdaq. Orchestra BioMed operates in the medical technology and biomedical devices sector. For complete filing history, deal terms, and real-time SPAC data on OBIO and thousands of other transactions, sign up for full access at SpacDesk.